Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ranolazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ranolazine SCHEMBL612077 | 1.00 | LMNA (1.00) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL6391141 | 0.99 | CYP3A4 (1.00) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL124666 | 0.99 | CYP3A4 (1.00) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL1495098 | 0.99 | CYP3A4 (1.00) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL30296819 | 0.99 | CYP3A4 (1.00) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL1534086 | 0.99 | CYP3A4 (1.00) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL7933344 | 0.99 | CYP3A4 (1.00) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL124665 | 0.99 | CYP3A4 (1.00) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL14841986 | 0.98 | CYP3A4 (0.98) | LMNABLMPMP22NPSR1CYP3A4 | |
| Ranolazine SCHEMBL3462812 | 0.98 | CYP3A4 (0.98) | LMNABLMPMP22NPSR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 684 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861254-B1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | ACESION PHARMA APS (DK) | 2020-04-29 | — | — | EP | claimed |
| CN-110898024-A | Pharmaceutical composition for treating angina pectoris and preparation method thereof | 卓和药业集团有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-110859843-A | Pharmaceutical composition for treating arteriosclerosis complicated with angina pectoris and preparation method thereof | 卓和药业集团有限公司 | 2020-03-06 | — | — | CN | claimed |
| CN-110812344-A | Pharmaceutical composition for treating diabetes complicated with angina pectoris and preparation method thereof | 卓和药业集团有限公司 | 2020-02-21 | — | — | CN | claimed |
| CN-109694888-A | The method for improving diacid fermentation yield | 陈凯南 | 2019-04-30 | — | — | CN | claimed |
| US-20170304388-A1 | NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION | LAUNX BIOMEDICAL CO., LTD. (TW) | 2017-10-26 | — | — | US | claimed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-20150164871-A1 | Pharmaceutical Compositions for Combination Therapy | ACESION PHARMA (DK) | 2015-06-18 | — | — | US | claimed |
| EP-2861254-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | Acesion Pharma ApS (DK) | 2015-04-22 | — | — | EP | claimed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | claimed |
| WO-2009055783-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | claimed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | claimed |
| CN-1891218-A | Ranolazine hydrochloride slow-release preparation and its preparing method | QILU PHARMACEUTICAL CO LTD (CN) | 2007-01-10 | — | — | CN | claimed |
| CN-1868477-A | Formula of Reynoldazine hydrochloride prepn. | PHARMACEUTICAL GEN PLANT HAYAO (CN) | 2006-11-29 | — | — | CN | claimed |
| CN-1248690-C | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease | HUAZHONG TEACHER S UNIVERSITY (CN) | 2006-04-05 | — | — | CN | claimed |
| WO-2006008753-A1 | CRYSTALLINE AND AMORPHOUS FORM OF RANOLAZINE AND THE PROCESS FOR MANUFACTURING THEM | UNICHEM LABORATORIES LIMITED (IN) | 2006-01-26 | — | — | WO | claimed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | claimed |
| CN-1562024-A | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease | HUAZHONG TEACHER S UNIV (CN) | 2005-01-12 | — | — | CN | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-5906988-A | PROTECTING MYOCARDIUM AGAINST GLOBAL ISCHAEMIC DAMAGE INDUCED BY CARDIOPLEGIA AND PROTECTING NEURONAL TISSUE AGAINST ISCHAEMIC DAMAGE RESULTING FROM CARDIAC OR NON-CARDIAC CONDITIONS COMPRISES ADMINISTERING RANOLAZINE OR DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1999-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | SCN5A 2144/4885LMNA 326/4885BLM 4371/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | SCN5A 43/4885LMNA 2103/4885BLM 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.